Although it may seem counterintuitive for cancer to exhibit decreased PKM2 activity in the context of the Warburg effect, it has been suggested that this reduction in PKM2 activity actually enhances the flow of glycolytic intermediates into biosynthetic pathways. The gene discussed is PKM; the disease is cancer.